Close Menu
Home » Qiagen JAK2 Test Gets FDA Clearance for Additional Blood Cancer Types

Qiagen JAK2 Test Gets FDA Clearance for Additional Blood Cancer Types

Jan 23, 2018
|
staff reporter

NEW YORK (GenomeWeb) – Qiagen said after the close of the market on Tuesday that it received US Food and Drug Administration clearance for its Ipsogen JAK2 RGQ PCR Kit for additional use in the diagnosis of all myeloproliferative neoplasms (MPNs).

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Ways to Make the Move

A new report offers ways for small, society publishers to transition to Plan S standards, ScienceInsider says.

Fire at Russian Pathogen Lab

A gas explosion sparked a fire at a Russian laboratory that stores dangerous pathogens, the Guardian reports.

Proteins From the Past

Researchers turn to protein analysis to examine an ancient rhino sample, Smithsonian.com reports.

PNAS Studies Look at Diabetes Susceptibility, S. Aureus Subpopulations, More

In PNAS this week: C2CD4A gene involved in insulin secretion, chromosome rearrangements in recurring S. aureus infections, and more.

What's Popular?

In Regulatory News & FDA Approvals

  1. Applied BioCode Submits Respiratory Pathogen Panel to FDA

  2. LumaCyte Obtains CE Mark for Cellular Analysis Platform

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.